UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 ORor 15(d) of the

~~of The~~ Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August ~~June 14~~2, 2017

PHARMERICA CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-33380	87-0792558
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1901 Campus Place Louisville, Kentucky		40299
(Address of principal executive offices)		(Zip Code)

1901 Campus Place

Louisville, Kentucky 40299

(Address of principal executive offices) (Zip Code)

(502) 627-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 52.0702 ~~Submission~~Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition.

~~The~~On ~~2017~~August ~~Annual~~2, ~~Meeting~~2017, ~~of Stockholders of~~ PharMerica Corporation (the “Company”) ~~was~~issued ~~held~~a onpress release announcing results of operations for the second quarter ended June 1430, 2017, a copy of which is attached as Exhibit 99.1.

1.Item ~~The Company’s stockholders approved the election of the following seven directors for a term to expire at the Annual Meeting of Stockholders in 2018~~9.01 ~~The~~Financial ~~votes~~Statements ~~for~~and ~~each director were as follows:~~Exhibits.

Name	For		Withheld Authority		Broker Non- Votes
Frank E. Collins, Esq.		26,260,958		145,961		3,402,081
W. Robert Dahl, Jr.		26,314,884		92,035		3,402,081
Marjorie W. Dorr		26,322,611		84,308		3,402,081
Patrick G. LePore		26,295,796		111,123		3,402,081
Geoffrey G. Meyers		26,301,570		105,349		3,402,081
Robert A. Oakley, Ph.D.		26,313,704		93,215		3,402,081
Gregory S. Weishar		26,317,775		89,144		3,402,081

(d) Exhibits

299.1 ~~The~~Press ~~Company’s~~Release ~~stockholders voted upon the ratification~~ of ~~the~~PharMerica ~~appointment~~Corporation ofdated ~~KPMG~~August ~~LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31~~2, 2017. ~~The votes on this proposal were as follows:~~

For		Against		Abstained
29,719,945		81,839		7,216

SIGNATURES

3.Pursuant ~~The~~to ~~Company’s~~the ~~stockholders~~requirements ~~voted~~of ~~upon~~the ~~and~~Securities Exchange ~~approved,~~Act byof ~~advisory vote~~1934, the ~~compensation~~registrant ofhas ~~the~~duly ~~Company’s~~caused ~~named~~this ~~executive~~report ~~officers.~~to ~~The~~be ~~votes~~signed on ~~this~~its ~~proposal~~behalf ~~were~~by asthe ~~follows:~~undersigned hereunto duly authorized.

For		Against	Abstained	Broker Non-Votes
	PHARMERICA CORPORATION
25,173,015		1,181,809	52,095	3,402,081
Date: August 2, 2017	By:	/s/ Robert E. Dries
		Robert E. Dries
		Executive Vice President and Chief Financial Officer

4.Exhibit The Company’s stockholders voted upon and approved, by advisory vote, one year as the frequency of the advisory vote on executive compensation in future years. The votes on this proposal were as follows:Index

One Year	Two Years	Three Years	Abstained	Broker Non-Votes
Exhibit No.	Description
19,874,255	11,468	6,475,964	45,232	3,402,081
99.1	Press Release of PharMerica Corporation dated August 2, 2017.

5. The Company’s stockholders voted upon and approved, by advisory vote, a stockholder proposal regarding simple majority vote. The votes on this proposal were as follows:

For		Against		Abstained		Broker Non-Votes
23,545,772		2,803,577		57,570		3,402,081

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHARMERICA CORPORATION
Date: June 19, 2017	By:	/s/ Thomas Caneris
		Thomas Caneris
		Senior Vice President, General Counsel and Secretary

Filing Compare · PharMerica CORP